Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intravitreal anti-vascular endothelial growth factor (VEGF) therapy is now considered the gold standard for the treatment of various retinal disorders. As therapy has evolved, so too have the treatment regimens employed by physicians in clinical practice; however, visual outcomes observed in the real world have typically not reflected those reported in clinical trials. Possible reasons for this include a lack of consensus on treatment regimens and a lack of clarity about what the aims of treatment should be. METHODS: The Vision Academy Steering Committee met to discuss the principles of an ideal treatment regimen, using evidence from the literature to substantiate each point. Literature searches were performed using the MEDLINE/PubMed database (cut-off date: March 2016) and restricted to English-language publications. Studies with fewer than ten patients were excluded from this review. RESULTS: The Steering Committee identified the following four key principles for the ideal treatment regimen for anti-VEGF management of retinal diseases: 1. Maximize and maintain visual acuity (VA) benefits for all patients 2. Decide when to treat next, rather than whether to treat now 3. Titrate the treatment intervals to match patients' needs 4. Treat at each monitoring visit. CONCLUSIONS: It is proposed that the adoption of a proactive and more personalized approach in the clinic such as a treat-and-extend regimen will lead to benefits for both the patient and the physician, through a reduction in the associated treatment burden and better utilization of clinic resources. Implementation of the four principles should also lead to better VA outcomes for each patient, with a minimized risk of vision loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 1×
“These may be small or negligible at each event, but can accumulate and have significant long-term consequences, as demonstrated in patients with severe hemophilia A [82] and multiple sclerosis [83].”
BackgroundRanibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.011 · Cited by 822 · cited 4×
“Studies in AMD, DME, and RVO have shown intravitreal aflibercept 2q8 to be equally as efficacious as intravitreal aflibercept 2q4 [40, 46, 97] and, in nAMD, also equivalent to ranibizumab 0.”
BackgroundMethodResultInfluentialConsequences of Driving Cessation: Decreased Out-of-Home Activity Levels
Marottoli, R. A., de Leon, C. F. M., Glass, T. A., Williams, C. S., Cooney, L. M., & Berkman, L. F. (2000) · The Journals of Gerontology Series B: Psychological Sciences and Social Sciences · doi:10.1093/geronb/55.6.s334 · Cited by 728
Maguire, M. G., Martin, D. F., Ying, G.-S., Jaffe, G. J., Daniel, E., Grunwald, J. E., Toth, C. A., Ferris, F. L., & Fine, S. L. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.045 · Cited by 708
Holz, F. G., Amoaku, W., Donate, J., Guymer, R. H., Kellner, U., Schlingemann, R. O., Weichselberger, A., & Staurenghi, G. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.019 · Cited by 413
Schmidt-Erfurth, U., Eldem, B., Guymer, R., Korobelnik, J.-F., Schlingemann, R. O., Axer-Siegel, R., Wiedemann, P., Simader, C., Gekkieva, M., & Weichselberger, A. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.09.004 · Cited by 387
Singer, M. A., Awh, C. C., Sadda, S., Freeman, W. R., Antoszyk, A. N., Wong, P., & Tuomi, L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.016 · Cited by 356
Heier, J. S. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.11.1532 · Cited by 304
(2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.11.031 · Cited by 283
Lim, J. H., Wickremasinghe, S. S., Xie, J., Chauhan, D. S., Baird, P. N., Robman, L. D., Hageman, G., & Guymer, R. H. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.09.013 · Cited by 141 · cited 1×
“[79] investigated the effects of a delay in treatment on VA outcomes.”
BackgroundFauser, S., Schwabecker, V., & Muether, P. S. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.05.025 · Cited by 85 · cited 1×
“This intra-individual stability has also been demonstrated in experiments investigating the suppression of VEGF by intravitreal aflibercept [91], which has been shown to suppress VEGF in the eyes of patients with nAMD for a mean of 71 days [91].”
MethodZhu, M., Chew, J. K., Broadhead, G. K., Luo, K., Joachim, N., Hong, T., Syed, A., & Chang, A. A. (2015) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-014-2799-8 · Cited by 38
Cited by
Ohji, M., Takahashi, K., Okada, A. A., Kobayashi, M., Matsuda, Y., Terano, Y., for the ALTAIR Investigators, Ohji, M., Hanemoto, T., Kaga, T., et al. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01236-x · Cited by 256
Mitchell, P., Holz, F. G., Hykin, P., Midena, E., Souied, E., Allmeier, H., Lambrou, G., Schmelter, T., Wolf, S., & on behalf of the ARIES study investigators (2021) · Retina · doi:10.1097/iae.0000000000003128 · Cited by 101
Touchard, E., Benard, R., Bigot, K., Laffitte, J.-D., Buggage, R., Bordet, T., & Behar-Cohen, F. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.013 · Cited by 32
Sivaprasad, S., Bailey, C., Downey, L., Gilbert, R., Gale, R., Kotagiri, A., Mahmood, S., Morgan-Warren, P., Napier, J., Narendran, N., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2362278 · Cited by 15
“Most anti-VEGF treatments have been approved for treat and extend dose regimens, the aim of which is to maintain optimal clinical outcomes with reduced injection frequency compared to fixed and pro re nata regimens 22–26 .”
Background
Metadata
- Authors
- The Vision Academy Steering Committee, Lanzetta, P., & Loewenstein, A.
- Venue
- Graefe's Archive for Clinical and Experimental Ophthalmology
- Published
- 2017-05-19
- Volume
- 255
- Issue
- 7
- Pages
- 1259-1273
- ISSN
- 0721-832X (ISSN-L)
- 1435-702X
- OpenAlex
- W2616502721
- Cited by
- 180
- References
- 19
- FWCI
- 11.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.